aibioChromaDex (now Niagen Bioscience) adds Roth Capital to at-the-market program
Tickers NAGE
B. Riley Securities is removed from the program. Raymond James and Roth Capital Partners will continue as the sales agents.
Key facts
- Company
- Niagen Bioscience, Inc. (NASDAQ: NAGE)
- News type
- Financings
- Primary source
- Niagen Bioscience, Inc. 8-K (2024-11-21)
ChromaDex Corporation (now Niagen Bioscience, Inc.) entered into Amendment No. 1 to its At Market Issuance Sales Agreement on November 20, 2024. The original agreement is dated June 12, 2020 and governs the company's "at-the-market" equity offering program for its common stock. An at-the-market program lets a company sell shares from time to time into the public trading market through sales agents.
The amendment makes four changes. It revises the list of sales agents to include Roth Capital Partners, LLC. It removes B. Riley Securities, Inc., formerly B. Riley FBR, Inc., as a sales agent. It updates the notice provisions to match, and it makes other conforming changes.
As a result, Raymond James & Associates, Inc. and Roth Capital Partners will continue as the sales agents under the agreement.
The 8-K was filed on November 21, 2024. The amendment itself is filed as Exhibit 1.1 to the report.